 impella volatil continu remain construct name
morn report fiscal result bit shi top line
beat bit bottom line impella growth still difficult comp
sourc shortfal intern well ahead target
caus manag lower revenu outlook year updat certainli
fuel concern market size util impella howev believ
near-term opportun bottom account use impella per
quarter math goe would add quarterli revenu longer
term still believ efficaci devic outstand eventu becom
standard care keep us construct name
fiscal result littl top-lin ep beat penni
report fiscal result end june morn sale come
light estim reason modest short-fal
 impella revenu light target
sale strong nearli bogey gross margin
bp estim due unfavor geograph mix
off-set sg line yield ep penni ahead
estim
guidanc reduc follow fiscal shortfal linger headwind
 lower revenu guidanc year
previous addit lower oper margin outlook
would character mid-point new revenu guidanc rang
layup place estim slightli point new
revenu growth rate oper margin still repres best
medic technolog monopoli provid
takeaway call along investor still tri figur
exactli go domest impella util sure fda letter
rp factor lack rct impella said continu
believ util devic sick larg question market
size patient popul manag note intend increas util
account repres domest impella sale math
abl lift util cathet per quarter per center believ
around impella per center moment would yield anoth quarterli
revenu annual although anticip take time believ
achiev beyond impella perform japan stellar
compani may use robust balanc sheet repurchas roughli
share outstand stock
ev/ci sale
debt total capit
develop manufactur circulatori support devic
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
stock thought earli trade today share give back gain
claw back soft fiscal result understand investor trepid outlook
impella go forward said continu believ technolog best
avail treat patient cardiogen shock eventu becom standard
care consequ view recent result rough patch compani
remain construct rate stock ow
price given perform quarter guidanc lower price target
previous price target base sale estim
assum net cash s/o previou target base
ev/ci sale assum net cash s/o
sourc compani report piper jaffray co estim
page
good gener incom expens net incom net incom analysi gross gener analysisu impella impella abiom
thousand except per share data
good sold
good sold
percent sale
good sold
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
